3rd rev
- Khng dng cho tr em, ph n mang thai, ang cho con b - Khng dng cho ngi b d ng vi bt k thnh phn no ca sn phm - i tng ang dng thuc iu tr cn hi kin bc s trc khi dng (*) Lu , sn phm khng c tc dng thay th thuc cha bnh
As previously mentioned, hypoglycaemia risk is low with Mounjaro monotherapy but increases when combined with insulin or sulphonylureas
The concept also pushes brain-health research toward treat the whole person not just treat the brain. That alignment is powerful
STEP 1 showed 14.9% body weight reduction at 2.4 mg weekly SELECT trial : Cardiovascular outcomes study showing 20% MACE reduction in patients with obesity and established CVD without diabetes FLOW trial : Kidney outcomes data demonstrating renal protective effects Oral formulation : Rybelsus provides an oral dosing option at 7-14 mg daily Real-world data : Millions of prescriptions written, providing extensive post-marketing safety surveillance Survodutide Research# Survodutide's evidence base is growing but not yet mature: Phase 2 obesity trial : Demonstrated dose-dependent weight loss up to approximately 19% body weight reduction, exceeding typical GLP-1 monotherapy results Phase 2 MASH data : Histological improvement in liver biopsies, including reduction in hepatic steatosis and inflammation scores Phase 3 programs : Active Phase 3 trials for both obesity and MASH, with results anticipated to define the compound's clinical profile Mechanism validation : Clinical data support the dual mechanism concept, with evidence of both appetite reduction and increased energy expenditure Limitation : No regulatory approvals
However, incorporating pairwise comparisons between humanized E
